Request for Reconsideration afier Final Action
`
`Page 1 of 13
`
`PTO Fon'n 1930 (Rev 9/2007)
`
`OMB No. 0651-0050 (Exp. 4I30.‘2009)
`
`Request for Reconsideration after Final Action
`
`The table below presents the data as entered.
`
`
`
`Input Field
`
`Entered
`
`SERIAL NUMBER
`
`77378170
`
`LAW OFFICE ASSIGNED
`
`LAW OFFICE 101
`
`
`
`MARK SECTION (no change)
`
`
`
`
`
`
`
`
`
`
`
`The mark ARTHREX ACP was rejected under Trademark Act §2(d), 15 U.S.C. §1052(d), because the
`Examiner held the mark, when used on or in connection with the identified goods, so resembles the
`mark in United States Registration No. 3,099,070 for ACP for use with “surgical instrument for use in
`arthroscopic procedures” as to be likely to cause confusion, to cause mistake, or to deceive. Applicant
`respectfully disagrees.
`'
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Applicant has disclaimed the term ACP, which is an acronym for “autologous conditioned plasma.”
`Various articles and documents from various different sources on the Internet are attached as Exhibits
`A to P. These exhibits show numerous uses of the term “autologous conditioned plasma” and its
`associated acronym ACP. As described in the attached articles, “autologous conditioned plasma” is a
`concentration of a patient’s own platelets and growth factors that is injected into injured tissue to
`improve the healing of tendon, ligaments and orthopedic conditions. By injecting the “autologous
`conditioned plasma” into the injured area of the patient, the need for surgery could be reduced. As
`ACP is an acronym for “autologous conditioned plasma” and has been disclaimed, Applicant requests
`withdrawal of the rejection.
`
`Additionally, there is no likelihood of confusion between Registrant’s ACP mark and Applicant’s
`ARTHREX ACP mark as the goods employed with the two marks are different. Registrant’s mark is
`registered with use with a “surgical instrument for use in arthroscopic procedures.” Specifically,
`Registrant’s mark ACP is employed with a suture cutter or knot pusher (Exhibit Q), as shown on
`Registrant’s website www.ortheon.com (Ortheon was acquired by Tendon Technology, Ltd., the listed
`Registrant). These goods are used during an arthroscopic surgical procedure. In contrast, Applicant’s
`goods are syringes used to inject the “autologous conditioned plasma” to improve healing of an injury
`with the intention of avoiding surgery. The goods used with the two marks are different, and therefore
`a likelihood of confusion is unlikely.
`-
`
`Finally, there is no likelihood of confusion due to the sophistication of the consumers who purchase
`these goods. The purchasers of both Applicant’s and Registrant’s goods are highly educated and
`would use caution and thought when purchasing goods for use in the medical industry. For example,
`the purchasers could be physicians or hospitals. These goods are not as impulse purchases, and a
`purchaser would employ thought and consideration when selecting and purchasing medically related
`
`
`
`
`
`
`
`
`
`
`
`
`file://\\ticrs-ais—01\ticrsexport\HtmlToTifiInput\R_FR00012009_05_06_l3_16_29_TTABO8. ..
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 2 of 13
`
`
`
`EVIDENCE SECTION
`
`
`
`
`
`
`
`
`
`
`ORIGINAL
`PDF FILE
`
`§3]§“Ff&1§fs‘f)D
`(2 pages,
`
`ORIGINAL
`PDF FILE
`
`(3 pages,
`
`ORIGINAL
`PDF FILE
`
`§§§;{IEL1gf§)D
`(1 page)
`
`ORIGINAL
`mm mm
`
`§§§;EIL1}:T§D
`(3 pages,
`‘ ’
`
`http://tgate/PDF/RFR/2009/O4/23/20090423 14425980945 8-
`77378170-017_O01/evi_6840248192-143232709_._A.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR0002.JPG
`
`\\TIC RS \EXPORT6\IM AGE OUT6\773\78 1\773 78 1 70\xml3
`\RF R0003 . JPG
`
`http : //tgate/PDF/RFR/2009/04/23/20090423 14425 980945 8-
`
`77378170-017_002/evi_6840248192-143232709_._B.pdf
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR0004.JPG
`
`\\TICRS\EXPORT6\IM AGE OUT6\773 \7 81\773 78170\xml3
`\RF R0005. JPG
`
`\\TIC RS \EXPORT6\IMAGEOUT6\773\78 1\773 78170\xm13
`\RFR0006. JPG
`
`
`
`
`
`http://tgate/PDF/ RFR/2009/04/23/20090423 144259809458-
`77378170-017_003/eVi_6840248192-143232709_._C.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`\RFROO07.JPG
`
`http://tgate/PDF/RFR/2009/04/23/20090423 14425980945 8-
`773 78170-017_OO4/evi_6840248 192-143 232709_._D.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
` ;&
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFR0009.JPG
`
`
`
` \\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`
`\RFROOl0.JPG
`
`
`
`
`
`
`
`
`
`
`
`
`
`.
`
`
`
`
`
`
`
`
`ORIGINAL
`PDF FILE
`
`http://tgate/PDF/RFR/2009/O4/23/20090423 14425980945 8-
`77378170-017_OO5/evi_6840248192-143232709_.wE.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`\_12_F_1<_tmi
`
`
`
`1§I‘)’§;IEL1}:Tg‘3D
`(2 pages)
`‘ ’
`
`file://\\ticrs-ais-01\ticrsexport\HtmlToTifl1nput\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 3 of 13
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`
`\RFR00 1 2.JPG
`
`
`
`
`http://tgate/PDF/RFR/2009/04/23/20090423 14425980945 8-
`77378170-017_006/eVi_6840248192-143232709_._F.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xn1l3
`\RFROO13.JPG
`
`ORIGINAL
`PDF FILE
`
`‘
`
`
`
`(4 pages)
`
`\\TICRS \EXPORT6\IM AGEOUT6\773\7 81\77378170\xm13
`\RF R00 1 4. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773 \7 81\773 78170\xml3
`\RF R00 1 5 . JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR0016.JPG
`
`http://tgate/PDF/RFR/2009/O4/23/20090423 14425980945 8-
`77378170-017_O07/evi_6840248192-143232709_._G.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xml3
`EF
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\R_FR0018.JPG
`
`ORIGINAL
`PDF FILE
`
`I°,§§FV,IELI;f§)D
`(2 pages)
`
`ORIGINAL
`PDF FILE
`
`1
`
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-
`77378170-017_008/evi_6840248192-143232709_._H.pdf
`
`
`
`
`
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFR0019.JPG
`
`http://tgate/PDF/RFR/2009/O4/23/20090423 144259809458-
`77378170—017_009/evi_6840248192-143232709_._I.pdf
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\.781\77378l70\xm13
`BF_
`
`http://tgate/PDF/RFR/2009/O4/23/20090423144259809458-
`77378170-017_0lO/eVi__6840248192-143232709__._J.pdf
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFROO21.JPG
`———~——
`
`http://tgate/PDF/RFR/2009/04/23/20090423 144259809458-
`77378170-017_011/evi_6840248192-143232709_._K.pdf
`
`_
`
`‘r§§§FVTEL11“:'f§"-)9
`(1 page)
`
`ORIGINAL
`PDF FILE
`
`1‘j§§‘F'&I§%D
`(1 page)
`
`ORIGINAL
`PDF mm
`
`(1 page)
`
`‘ ’
`
`ORIGINAL
`pm FILE
`
`
`
`PDF FILMS)
`
`
`
`
`
`
`CONVERTED
`
`‘
`
`v
`
`(2 pages)
`
`-4-‘?
`
`\\TIC RS \EXPORT6\IM AGEOUT6\773 \7 81\773 78170\xml3
`\RF R0023 . JPG
`
`
`
`file://\\ticrs-ais-01\ficrsexport\HtmlToTifiInput\RFR00012009_05__06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 4 of 13
`
`
`
`ORIGINAL
`PDF FILE
`
`
`
`http://tgate/PDF/RFR/2009/O4/23/20090423144259809458-
`77378170—017_012/eVi_6840248192-143232709_._L.pdf
`
` COYVERTED
`Pm‘? FILMS)
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378 170\xm13
`(8 pages)
`\_RF_Roo24.JPQ
`
`
`
`
`
`
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\77378 170\xm13
`\RFR0025.JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`\RF R0026. JPG
`
`\\TIC RS \EXP ORT6\IM AGEOUT6\773 \78 1\773 78 170\xml3
`\RF R0O27.JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\773 78170\xml3
`\RF R0028.JPG
`
`\\TIC RS\EXPORT6\IM AGEOUT6\773\7 81\77378170\xml3
`\RFR002 9.JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RF R003 0.JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\773 78170\xml3
`\RFR003 1 .JPG
`
`ORIGINAL
`PDF FILE
`
`http://tgate/PDF/RFR/2009/04/23/20090423 144259809458-
`773 78 170-017_0 1 3/eVi_6 840248 192- 143232709_. _M.pdf
`
`::'{1"11g1){0S3\§)J{11’C(})RT6\II\/IAGEOUT6\773\781\77378170\xml3
`
`CONVERTED
`
`PDF FILMS)
`
`
`
`(2 pages)
`
`
`
`
`
`
`
`ORIGINAL
`PDF FILE
`
`CONVERTED
`PDF FILE(S)
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFRO033.JPG
`
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-
`77378170-017_014/evi_6840248192-143232709_._N.pdf
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\78 1\77378 170\xm13
`\RF R003 4. JPQ
`
`
`
`
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\773781 70\xml3
`\RFR0036.JPG
`
`\\TIC RS\EXPORT6\IM AGEOUT6\773\781\773 78 1 70\xml3
`\RF R003 5.JPG
`
`
`
`
` \\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`
`\RFR0037.JPG
`
`
`\\TIC RS \EXPORT6\IMAGEOUT6\773\78 1\773 78170\xml3
`\RFR0038.JPG
`
`file://\\ticrs-ais—01\ticrsexport\Htm1ToTifi‘Input\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 5 of 13
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR003 9. JPG
`
`
`
`\\TICRS\EXPORT6\IM AGEOUT6\773\781\77378 l70\xml3
`\RF R0040. JPG
`
`\\TIC RS\EXP ORT6\IM AGEOU T6\773\7 81\773 78170\xml3
`\RFR004 1 . JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RF R0042. JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\78 1\773 78 170\xml3
`\RF R0043. JPG
`
`\\TICRS \EXPORT6\IM AGEOUT6\773\7 81\773 78 170\xml3
`\RFR0044.JPG
`
`\\TIC RS \EXPORT6\IM AGEOUT6\773\7 81\77378170\xml3
`\RF R0045. JPG
`
`\\TICRS\EXPORT6\IM AGEOUT6\773\78 1\77378 170\xm13
`\RFR0046. JPG
`
`
`
`
`
`\\TICRS\EXPORT6\IM AGEOUT6\773\781\773 78170\xm13
`\RF R0047. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFRO048.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFROO49.JPG
`
`\\T_ICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFROO50.JPG
`
`
`
`http://tgate/PDF/RFR/200 9/04/23/20090423 14425980945 8-
`77378170-017_O15/evi_6840248192-143232709_._O.pdf
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR0051.JPG
`
`\\TICRS \EXP ORT6\IMAGEOUT6\773\78 1\773 78 1 70\xml3
`\RF R00 5 2. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\773 78170\xml3
`\RFROO53.JPG
`
`ORIGINAL
`mm FILE
`
`gggflfg”
`(25 pages)
`
`\\TICRS_\EXPORT6\IMAGEOUT6\773\7 81\77378170\xml3
`\RF R005 4. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\78 1\77378170\xm13
`\RF R005 5. JPG
`
`\\TIC RS \EXPOR'I'6\IM AGEOUT6\773\7 8 1\77378 170\xm13
`
`
`
`file://\\ticrs-ais-01\.ticrsexport\HtmlToTiff[nput\RFR00012009_05_06_13_16_29_TTABO8...
`
`5/6/2009
`
`

`
`Request for Reconsideration after Final Action
`
`Page 6 of 13
`
`
`
`
`
`
`
`
`
`
`
`\RFR0056.JPG
`
`\\TIC RS\EXPORT6\IM AGE 0UT6\773\78 1\77378 1 70\xml3
`\RF R00 5 7.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xml3
`\RFR00 5 8.J PG
`
`\\TICRS \EXPORT6\IMAGEOUT6\773 \7 81\77378 170\xm13
`\RF R00 5 9. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RF R0060. JPG
`
`\\TIC RS\EXPORT6\IM AGEOUT6\773\7 81\773781 70\xml3
`\RF R006 1 .JPG
`
`\\TICRS \EXPORT6\IM AGE OUT6\773\7 81\77378170\xml3
`\RF R0062. JPG
`
`\\TICRS \EXPORT6\IM AGEOUT6\773\7 81\773781 70\xml3
`\RF R0063 . JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\78l\77378170\xml3
`\RF R0064.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\773 78 l 70\xml3
`\RF R006 5 .JPG
`
`\\TIC RS\EXPORT6\IM AGEOUT6\773 \7 81\77378170\xm13
`\RF R0066. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\773 78 1 70\xml3
`\_Rfl1Q.0flJP_Ci
`
`\\TIC RS \EXPORT6\IM AGEOUT6\773\7 8 1\77378 170\xm13
`\RF R0068.JPG
`
`\\TIC RS\EXPORT6\IM AGEOUT6\773\7 81\77378170\xm13
`\RFR0069.JPG
`’
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RF R0070.JPG
`
`\\TIC RS \EXPORT6\IMAGEOUT6\773\7 81\77378170\xml3
`\RF R007 1 . JPG
`
`\\TIC RS\EXPORT6\IMAGEOUT6\773\781\773 78 170\xml3
`
`\RFR@2.JPG_
`
`'
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`\RFR0074.JPG
`
`
`
`
`
`file://\\ticrs-ais-01\ticrsexport\HtmlToTifi"Input\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 7 of 13
`
`\\TICRS\EXPORT6\IM AGE OUT6\773\78 1\773 78 1 70\xml3
`\RFROO75 . JPG
`
`ORIGINAL
`PDF FILE
`
`CONVERTED
`
`
`
`PDF FILMS)
`
`(9 Pages)
`
`
`
`\\TICRS\EXPORT6\IM AGEOUT6\773\78 1\77378 1 70\xml3
`\RFR0077. JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\773 78170\xml3
`\RFR0078. JPG
`
`.
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFR0079.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFR0080.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378l70\xm13
`\RFR0081.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`
`\RFROO82.JPG
`
`A
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFR0083.JPG
`
`
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\RFR0084.JPG
`
`http://tgate/PDF/RFR/2009/04/23/20090423 144259809458-
`77378170-017_O17/evi_6840248192-143232709_._Q.pdf
`
`ORIGINAL
`PDF FILE
`
`
`
`
`
`
`
`
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xm13
`\£F_R0_0&lE
`
`
`
`\ TICRS\EXPORT6\IMAGEOUT6\773\781\773781 70\Xml3
`\RFRO086.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378170\xml3
`\RFROO87.JPG
`
`\\TICRS\EXPORT6\IMAGEOUT6\773\781\77378 170\xml3
`\RFR0088.JPG
`
`‘rE]‘)’FNVFHEf;g3)D
`(4 pages)
`
`DESCRIPTION OF EVIDENCE FILE
`
`Articles f-'ror'n websites obtained from the Internet showing
`the descriptive use of ACP
`
`ADDITIONAL STATENIENTS SECTION
`
`DISCLAIMER
`
`No claim is made to the exclusive right to use ACP apart
`from the mark as shown.
`
`
`
`
`
`file://\\ticrs-ais-01\ticrsexpoIt\HtmlToTifflnput\RFR00012009_05_O6_13_16_29_TTAB08...
`
`5/6/2009
`
`
`
`
`
`
`
`
`
`
`
`http://tgate/PDF/RFR/2009/O4/23/20090423144259809458-
`77378170-017_016/evi_6840248192-143232709_._P.pdf
`
`
`
`
`
`_
`
`:‘i%fPI‘([:§(;S_>l:‘",}J(Il’CC})RT6\IMAGEOUT6\773\78 1\77378170\)sII1l3
`
`'
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 8 of 13
`
`
`
`ACP appearing in The mark means or signifies autologous
`conditioned plasma in the relevant trade or industry or as
`applied to the goods/services listed in the application.
`
`
`
`
`
`
`USPTO/RFR-68.40.248. 192-2
`0090423144259809458-77378
`170-430371fb94536a990d762
`f2faea27b58c9 d-N/A-N/A-20
`090423143232709850
`
`
`
`
`
`
`
`
`
`
`
`
` SIGNIFICANCE OF MARK
`
`SIGNATURE SECTION
`
`DECLARATION SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`DATE SIGNED
`
`RESPONSE SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY‘S POSITION
`
`DATE SIGNED
`
`AUTHORIZED SIGNATORY
`
`CONCURRENT APPEAL NOTICE FILED
`
`FILING INFORMATION SECTION
`
`TEAS STAMP
`
`
`
`vvvvvV00vMuun-Irv-v~v-wvvv-haul:-anU-v-vvvvvuuuuwv-I--In-no540000II-urvItV-lowv-VIv-ItosoU-Icu-ua-V-v-vvvuV-vu-J-uuuv-V-abeIIU-IIauvuu-av-A-v~Ivvwouuu-bunoU--4-vvv-uuouwluvvvv-vvUuu-IvuvvvVvuuU-luv-avvvwvuna-uuuvw-o-»Ivuuuuuvvvv0\
`
`PTO Form 1930 (Rev 9/2007)
`
`OMB No. 0651-0050 (Exp. 4/30/2009)
`
`Request for Reconsideration after Final Action
`
`To the Commissioner for Trademarks:
`
`Application serial no. 77378170 has been amended as follows:
`
`ARGUMENT(S)
`In response to the substantive refusal(s), please note the following:
`
`The mark ARTHREX ACP was rejected under Trademark Act §2(d), 15 U.S.C. §l052(d), because the
`Examiner held the mark, when used on or in connection with the identified goods, so resembles the
`mark in United States Registration No. 3,099,070 for ACP for use with “surgical instrument for use in
`
`file://\\ticrs-ais—01\ticrsexport\HtmlToTifiInput\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 9 of 13
`
`arthroscopic procedures” as to be likely to cause confusion, to cause mistake, or to deceive. Applicant
`respectfully disagrees.
`
`Applicant has disclaimed the term ACP, which is an acronym for “autologous conditioned plasma.”
`Various articles and documents from various di1Terent sources on the Internet are attached as Exhibits A
`to P. These exhibits show numerous uses of the term “autologous conditioned plasma” and its
`associated acronym ACP. As described in the attached articles, “autologous conditioned plasma” is a
`concentration of a patient’s own platelets and growth factors that is injected into injured tissue to
`improve the healing of tendon, ligaments and orthopedic conditions. By injecting the “autologous
`conditioned plasma” into the injured area of the patient, the need for surgery could be reduced. As
`ACP is an acronym for “autologous conditioned plasma” and has been disclaimed, Applicant requests
`withdrawal of the rejection.
`
`Additionally, there is no likelihood of confiision between Registrant’s ACP mark and Applicant’s
`ARTHREX ACP mark as the goods employed with the two marks are different. Registrant’s mark is
`registered with use with a “surgical instrument for use in arthroscopic procedures.” Specifically,
`Registrant’s mark ACP is employed with a suture cutter or knot pusher (Exhibit Q), as shown on
`Re gistrant’s website www.ortheon.com (Ortheon was acquired by Tendon Technology, Ltd., the listed
`Registrant). These goods are used during an arthroscopic surgical procedure. In contrast, Applicant’s
`goods are syringes used to inject the “autologous conditioned plasma” to improve healing of an injury
`with the intention of avoiding surgery. The goods used with the two marks are different, and therefore a
`likelihood of confusion is unlikely.
`
`Finally, there is no likelihood of confusion due to the sophistication of the consumers who purchase
`these goods. The purchasers of both Applicant’s and Registrant’s goods are highly educated and would
`use caution and thought when purchasing goods for use in the medical industry. For example, the
`purchasers could be physicians or hospitals. These goods are not as impulse purchases, and a purchaser
`would employ thought and consideration when selecting and purchasing medically related goods.
`
`EVIDENCE
`Evidence in the nature of Articles from websites obtained from the Internet showing the descriptive use
`of ACP has been attached.
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/0 4/23/20090423 14425980945 8-77378170-017_001/evi_6840248192-
`14323 2709_._A.pdf
`Converted PDF file(s) (2 pages)
`Evidence-1
`Evidence-2
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_0O2/evi_6840248192-
`143232709_._B.pdf
`Converted PDF file(s) (3 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/2009042314425980945 8-77378170—0l7_003/eVi_6840248192-
`l43232709_._C.pdf
`
`file://\\ticrs-ais-01\ticrsexport\HtmlToTifiInput\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration afler Final Action
`
`Page 10 of 13
`
`Converted PDF file(s) (1 page)
`EVidence— 1
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/2009042314425980945 8-77378170-017_004/evi_6840248192-
`143232709_._D.pdf
`Converted PDF file(s) (3 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/2009042314425980945 8-77378170-017_005/evi_6840248192-
`143232709_._E.pdf
`Converted PDF file(s) (2 pages)
`Evidence-1
`
`Evidence-2
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_006/evi_6840248192-
`143232709_._F.pdf
`Converted PDF file(s) (4 pages)
`Evidenc e- 1
`Evidence-2
`
`Evidence-3
`Evidence-4
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_007/evi_6840248192-
`143232709_._G.pdf
`Converted PDF file(s) (2 pages)
`Evidenc e- 1
`Evidence—2
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_0O8/evi_6840248192-
`143232709_._H.pdf
`Converted PDF file(s) (1 page)
`Evidence-1
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_009/evi_6840248192-
`143232709_._I.pdf
`Converted PDF file(s) (1 page)
`Evidence-1
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/2009042314425980945 8-77378170-017_0l0/eVi_6840248192-
`143232709_._J.pdf
`Converted PDF file(s) (1 page)
`Evidence- 1
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_0l 1/eVi_6840248 192-
`l43232709_._K.pdf
`Converted PDF file(s) (2 pages)
`Evidence-1
`Evidence-2
`
`Original PDF file:
`
`file://\\ticrs-ais-O1\ticrsexport\HtmlToTifi'[nput\RFR00012009_05_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`Request for Reconsideration after Final Action
`
`Page 11 of 13
`
`http://tgate/PDF/RFR/2009/O4/23/20090423144259809458-77378170—017_012/evi_6840248192-
`143232709_._L.pdf
`Converted PDF fle(s) (8 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/2009042314425980945 8-77378170-017_O13/evi_6840248192-
`143232709_._M.pdf
`Converted PDF file(s) (2 pages)
`Evidence—1
`Evidence-2
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_O14/evi_6840248192-
`l43232709_._N.pdf
`'
`Converted PDF file(s) (17 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence—5
`Evidence-6
`Evidence-7
`Evidence-8
`Evidence-9
`Evidence- 10
`Evidence-11
`Evidence— 12
`Evidence-13
`Evidence- 14
`Evidence-15
`Evidence- 16
`Evidence- 17
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423144259809458-77378170-017_015/evi_6840248192-
`143232709_._O.pdf
`Converted PDF file(s) (25 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`
`Evide£c:2
`
`file://\\ticrs-ais-01\ticrsexp0rt\HtmlToTiffInput\RFR00012009_05_06_13_16_29_TTABO8...
`
`5/6/2009
`
`

`
`Request for Reconsideration after Final Action
`
`Page 12 of 13
`
`Evidence-10
`Evidence-11
`Evidence- 12
`
`Evidence-1;
`Evidence- 14
`Evidence-15
`Evide11ce- 16
`Evidence- 17
`Evidence— 18
`Evidence- 19
`
`Egience-2_0
`Evidence-21
`Evidence-22
`Evidence-23
`
`Evidence-24
`Evidence-25
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/04/23/20090423 144259809458-77378 170-O17_O16/evi_6840248192-
`143232709_._P.pdf
`Converted PDF file(s) (9 pages)
`Evidence-1
`
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`Evidence—9
`
`Original PDF file:
`http://tgate/PDF/RFR/2009/O4/23/20090423144259809458-77378170-O17_Ol7/evi_6840248192-
`143232709_._Q.pdf
`Converted PDF file(s) (4 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`
`ADDITIONAL STATEMENTS
`Disclaimer
`
`No claim is made to the exclusive right to use ACP apart from the mark as shown.
`
`Significance of wording, letter(s), or numeral(s)
`ACP appearing in the mark means or signifies autologous conditioned plasma in the relevant trade or
`industry or as applied to the goods/services listed in the application.
`
`SIGNATURE(S)
`Declaration Signature
`Ifthe applicant is seeking registration under Section 1(b) and/or Section 44 of the Trademark Act, the
`applicant has had a bona fide intention to use or use through the applicant's related company or licensee
`the mark in commerce on or in connection with the identified goods and!or services as of the filing date
`
`file://\\ticrs-ais-01\ticrsexport\HtmlToTifi'Input\RFR00012009_05_O6_l3_l6_29_TTABO8...
`
`5/6/2009
`
`

`
`Request for Reconsideration afier Final Action
`
`Page 13 of 13
`
`of the application. 37 C.F.R. Secs. 2.34(a)(2)(i); 2.34 (a)(3)(i); and 2.34(a)(4)(ii); and/or the applicant
`has had a bona fide intention to exercise legitimate control over the use of the mark in commerce by its
`members. 37 C.F. R. Sec. 2.44. If the applicant is seeking registration under Section 1(a) of the
`Trademark Act, the mark was in use in commerce on or in connection with the goods or services listed
`in the application as of the application filing date. 37 C.F.R. Secs. 2.34(a)(1)(i); and/or the applicant has
`exercised legitimate control over the use of the mark in commerce by its members. 37 C.F.R. Sec. 244.
`The undersigned, being hereby warned that willful false statements and the like so made are punishable
`by fine or imprisonment, or both, under 18 U.S.C. §l001, and that such willful false statements may
`jeopardize the validity of the application or any resulting registration, declares that he/she is properly
`authorized to execute this application on behalf of the applicant; he/she believes the applicant to be the
`owner of the trademark/service mark sought to be registered, or, if the application is being filed under 15
`U.S.C. §l051(b), he/she believes applicant to be entitled to use such mark in commerce; to the best of
`his/her knowledge and belief no other person, firm, corporation, or association has the right to use the
`mark in commerce, either in the identical form thereof or in such near resemblance thereto as to be
`likely, when used on or in connection with the goods/services of such other person, to cause confusion,
`or to cause mistake, or to deceive; that if the original application was submitted unsigned, that all
`statements in the original application and this submission made of the declaration signer's knowledge are
`true; and all statements in the original application and this submission made on information and belief
`are believed to be true.
`
`Date: 04/23/2009
`Signature: /karin h. butchko/
`Signatory's Name: Karin H. Butchko
`Signatory's Position: Attorney of record, Michigan bar member
`
`Request for Reconsideration Signature
`Signature: /karin h. butchko/ Date: 04/23/2009
`Signatory's Name: Karin H. Butchko
`Signatory's Position: Attorney of record, Michigan bar member
`
`The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of
`the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and other federal
`territories and possessions; and he/she is currently the applicant's attorney or an associate thereof; and to
`the best of his/her knowledge, if prior to his/her appointment another U.S. attorney or a Canadian
`attomey/agent not currently associated with his/her company/firrn previously represented the applicant
`in this matter: (1) the applicant has filed or is concurrently filing a signed revocation of or substitute
`power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to
`withdraw; (3) the applicant has filed a power of attorney appointing him/her in this matter; or (4) the
`applicant's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing
`him/her as an associate attorney in this matter.
`
`The applicant is not filing a Notice of Appeal in conjunction with this Request for Reconsideration.
`
`Serial Number: 77378170
`
`Internet Transmission Date: Thu Apr 23 14:42:59 EDT 2009
`TEAS Stamp: USPTO/RFR-68.40.248.192-2009042314425980
`945 8-77378170-430371fb94536a990d762f2fae
`a27b58c9d-N/A-N/A-20090423143232709850
`
`file://\\ticrs-ais-01\ticrsexpor‘t\HtmlToTifi‘1nput\RFR00012009_O5_06_13_16_29_TTAB08...
`
`5/6/2009
`
`

`
`PRP Therapy
`
`Accelerated natural healing for tendon and ligament injuries
`
`
`
`You hear a pop and feel the pain. Before you can say, "ice pack,
`please." your body has already dispatched its own emergency
`reponse expert — blood - to the site of the irjury.
`
`inside blood are platelets. These sticky, colorless components allow
`surface injuries. such as a paper cut, to clot Contained in platelets
`are growth factors. it is these growth factors that stimulate cell
`production and allow many types of irjuries - including tears in
`deep, soft tissues — to heal.
`
`This system, though highly effective for most injuries, leaves
`certain tissues at a biological disadvantage. Because tendons,
`ligaments and some other parts of your musculoskeietal
`system have a limited blood supply growth factors may
`not reach the injury site in sufficient quantities to promote rapid
`or complete cell repair. The result can be a longer or inadequate
`recovery, which may ultimately result in a need for surgical
`intervention.
`
`Platelet-rich plasma (PRP) is a concentration of a patients own
`platelets and growth factors used to improve the
`healing environment for certain tendon. ligament and other
`orthopedic conditions. This concentrate is also referred to as
`"atZr_toiogous'conditioned plasma (ACID). "
`
`Professional and amateur athletes value PRP therapy for its ability
`to help accelerate recovery from certain irjuries, reduce the need
`for surgery and allow a quicker return to sport. However, anyone
`with a tendon or ligament injury may be considered a candidate
`for PRP therapy
`
`Improving the healing environment
`with PRP therapy
`
`For more than 20 years, concentrated platelets have been
`used to help accelerate recovery following injury or surgery.
`Heart surgeons first used this treatment to promote wound
`healing and minimize blood loss. Specialists in many other
`disciplines, including orthopedics, followed.
`
`Currently, somejoint surgeons use concentrated platelets in
`patients to decrease bleeding at the surgical site, reduce the
`need for narcotic therapy after surgery. and improve range
`of motion. In sports medicine, PRP therapy has been
`recommended as an alternative to surgery in patients with
`chronic elbow tendonltis, a category of injuries that includes
`tennis elbow. For other tendon and ligament injuries. there
`are examples of PRP therapy accelerating injury recovery in
`athletes and allowing a faster return to sport.
`
`Who should consider PRP therapy?
`
`You may want to consider PRP therapy if you have been
`diagnosed with an injury to a tendon (attaches muscle to
`bone) or to a ligament (connects bone to bone). The injury
`can be either recent or chronic.
`
`Some common diagnoses include:
`- Tennis elbow, also called lateral elbow epicondylitis
`- Golfers elbow, also called medial elbow epicondylitis
`- Bursitis or impingement of the shoulder
`- Jumpers knee. also called patella tendonitis
`- Achilles’ tendonitis, located in the ankle
`
`- Plantar fasciitls, a common problem in the foot
`- Any ligament strain or sprain
`
`Early data suggests that concentrated platelets also may be
`beneficial in the treatment of arthritis in anyjoint.
`
`How is the procedure performed?
`
`if you believe you may be a candidate for PRP therapy, your
`problem will first be evaluated by your Tri Rivers physician,
`who will discuss the benefits and risks of treatment with you.
`You will then be scheduled for a return appointment, at
`which time the procedure will be performed.
`
`Prior to treatment, you will be advised to discontinue the use
`of antiinflammatory medications, such as ibuprofen, one
`week prior to your injection. Please notify your physician ‘
`if you have an allergy to epinephrine or bupivacaine
`(mancaine).
`
`Similar to a blood test, the procedure can be performed in
`Tri Rivers’ office in about 30 minutes. A small amount of
`
`blood is removed from your arm and specially prepared
`to separate the platelets from other components. The
`concentrated platelets are injected into the injured area, where
`they work by releasing growth factors to improve healing.
`
` ,
`
`Tri Rivers
`
`SURGICAL ASSOCIATES, lNC.
`
`Orthopedic Surgery and
`Musculoskeletal Medicine
`
`

`
`What happens after treatment?
`
`Accelerated Healing the Natural Way
`
`Many patients return to work the same day A splint may
`be needed temporarily to stabilize and support the injection
`site. Any localized soreness and discomfort can usually be
`relieved with ice and elevation of the affected area. Though
`uncommon, more severe pain may occur from the injection.
`This can be treated with prescription medications.
`
`You will be advised to decrease activities for a day or so
`and discontinue the use of anti-inflammatory medications for
`six weeks.
`
`One week following treatment, patients usually begin a
`rehabilitation program to further promote healing. A return
`to full activity will depend on your condition. PRP therapy can
`accelerate healing of acute injuries. but chronic problems may
`still require a longer recovery period. Your Tri Rivers physician
`will provide guidance on how quickly you can safely resume
`your activities.
`
`in general, patients can expect to see significant improvement
`in symptoms and a dramatic return of function. Traditional
`treatments such as medications. cortisone injections or
`
`surgery may no longer be needed.
`
`Are there risks associated with
`
`PRP therapy?
`
`Though uncommon. the risks of PRP therapy are similar to
`that of any injection. They include pain, infection, persistence
`or worsening of symptoms, blood clot, nerve injury, skin
`discoloration. calcification. scarring, loss of the fat in the
`affected area, and allergic reaction.
`
`if you experience these or other side effects, please contact
`your Tri Rivers physician toll-free at 1-866-874-7483.
`
`
`Is this treatment covered by insurance?
`
`insurance companies will typically cover your first evaluation
`with the physician. Like other newer procedures, however.
`most insurance companies do not cover PRP therapy Patients
`who choose to undergo PRP therapy must pay for the
`treatment out of pocket. For our patients’ convenience, Tri
`Rivers accepts cash, personal checks, MasterCard“ and Visa?‘
`
`Tri Rivers Surgical Associates
`Toll-free 1-866-874-7483
`www.tririversortho.com - info@tririversortho.com
`
`North Hills - Cranberry/Mars ~ Butler - Aspinwall
`
`S. Joshua Szabo. M.D., a sports medicine and shoulder
`specialist at Tri Rivers Surgical Associates, is one of only a
`few physicians in the western Pennsylvania area now offering
`PRP therapy as a treatment option for ligament. tendon and
`other orthopedic injuries. Dr. Szabos goal is to foster healing
`through minimally invasive techniques in an anatomic or
`natural manner. PRP therapy is certainly consistent with
`his philosophy.
`
`Learn more
`
`To learn whether PRP therapy is appropriate for you, please
`contact Tri Rivers toll-free at 1~866-874-7483. Our phone
`
`receptionist will be happy to schedule an appointment for
`you with Dr. Szabo. You may also request an appointment
`by visiting our website at www.tririversortho.i:om and clicking
`on the “Request an Appointment” link.
`
`
`
`References
`
`Anitua, E., et al. Autolog